Remission after acute treatment in children and adolescents with anxiety disorders

Findings from the CAMS

Golda S. Ginsburg*, Philip C. Kendall, Dara Sakolsky, Scott N. Compton, John Piacentini, Anne Marie Albano, John T. Walkup, Joel Sherrill, Kimberly A. Coffey, Moira A. Rynn, Courtney P. Keeton, James T. McCracken, Lindsey Bergman, Satish Iyengar, Boris Birmaher, John March

*Corresponding author for this work

Research output: Contribution to journalArticle

140 Citations (Scopus)

Abstract

Objective: To report on remission rates in anxious youth who participated in the Child/Adolescent Anxiety Multimodal Study (CAMS). The CAMS, a multisite clinical trial, randomized 488 children and adolescents (ages 7-17 years; 79 Caucasian; 50 female) with separation, social, and/or generalized anxiety disorder to a 12-week treatment of sertraline (SRT), cognitive behavioral therapy (CBT), their combination (COMB), or clinical management with pill placebo (PBO). Method: The primary definition of remission was loss of all study-entry anxiety disorder diagnoses; additional definitions of remission were used. All outcomes were rated by independent evaluators blind to treatment assignment. Predictors of remission were also examined. Results: Remission rates after 12 weeks of treatment ranged from 46 to 68 for COMB, 34 to 46 for SRT, 20 to 46 for CBT, and 15 to 27 for PBO. Rates of remission (i.e., achieving a nearly symptom-free state) were significantly lower than rates of response (i.e., achieving a clinically meaningful improvement relative to baseline) for the entire sample. Youth who received COMB had significantly higher rates of remission compared to all other treatment groups. Both monotherapies had higher remission rates compared to PBO, but rates were not different from each other. Predictors of remission were younger age, nonminority status, lower baseline anxiety severity, absence of other internalizing disorders (e.g., anxiety, depression), and absence of social phobia. Conclusions: For the majority of children, some symptoms of anxiety persisted, even among those showing improvement after 12 weeks of treatment, suggesting a need to augment or extend current treatments for some children.

Original languageEnglish (US)
Pages (from-to)806-813
Number of pages8
JournalJournal of Consulting and Clinical Psychology
Volume79
Issue number6
DOIs
StatePublished - Dec 1 2011

Fingerprint

Anxiety Disorders
Anxiety
Sertraline
Placebos
Cognitive Therapy
Therapeutics
Randomized Controlled Trials
Depression

Keywords

  • adolescents
  • anxiety
  • children
  • remission
  • treatment

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Ginsburg, G. S., Kendall, P. C., Sakolsky, D., Compton, S. N., Piacentini, J., Albano, A. M., ... March, J. (2011). Remission after acute treatment in children and adolescents with anxiety disorders: Findings from the CAMS. Journal of Consulting and Clinical Psychology, 79(6), 806-813. https://doi.org/10.1037/a0025933
Ginsburg, Golda S. ; Kendall, Philip C. ; Sakolsky, Dara ; Compton, Scott N. ; Piacentini, John ; Albano, Anne Marie ; Walkup, John T. ; Sherrill, Joel ; Coffey, Kimberly A. ; Rynn, Moira A. ; Keeton, Courtney P. ; McCracken, James T. ; Bergman, Lindsey ; Iyengar, Satish ; Birmaher, Boris ; March, John. / Remission after acute treatment in children and adolescents with anxiety disorders : Findings from the CAMS. In: Journal of Consulting and Clinical Psychology. 2011 ; Vol. 79, No. 6. pp. 806-813.
@article{a3703b908e454206b95b569005984c34,
title = "Remission after acute treatment in children and adolescents with anxiety disorders: Findings from the CAMS",
abstract = "Objective: To report on remission rates in anxious youth who participated in the Child/Adolescent Anxiety Multimodal Study (CAMS). The CAMS, a multisite clinical trial, randomized 488 children and adolescents (ages 7-17 years; 79 Caucasian; 50 female) with separation, social, and/or generalized anxiety disorder to a 12-week treatment of sertraline (SRT), cognitive behavioral therapy (CBT), their combination (COMB), or clinical management with pill placebo (PBO). Method: The primary definition of remission was loss of all study-entry anxiety disorder diagnoses; additional definitions of remission were used. All outcomes were rated by independent evaluators blind to treatment assignment. Predictors of remission were also examined. Results: Remission rates after 12 weeks of treatment ranged from 46 to 68 for COMB, 34 to 46 for SRT, 20 to 46 for CBT, and 15 to 27 for PBO. Rates of remission (i.e., achieving a nearly symptom-free state) were significantly lower than rates of response (i.e., achieving a clinically meaningful improvement relative to baseline) for the entire sample. Youth who received COMB had significantly higher rates of remission compared to all other treatment groups. Both monotherapies had higher remission rates compared to PBO, but rates were not different from each other. Predictors of remission were younger age, nonminority status, lower baseline anxiety severity, absence of other internalizing disorders (e.g., anxiety, depression), and absence of social phobia. Conclusions: For the majority of children, some symptoms of anxiety persisted, even among those showing improvement after 12 weeks of treatment, suggesting a need to augment or extend current treatments for some children.",
keywords = "adolescents, anxiety, children, remission, treatment",
author = "Ginsburg, {Golda S.} and Kendall, {Philip C.} and Dara Sakolsky and Compton, {Scott N.} and John Piacentini and Albano, {Anne Marie} and Walkup, {John T.} and Joel Sherrill and Coffey, {Kimberly A.} and Rynn, {Moira A.} and Keeton, {Courtney P.} and McCracken, {James T.} and Lindsey Bergman and Satish Iyengar and Boris Birmaher and John March",
year = "2011",
month = "12",
day = "1",
doi = "10.1037/a0025933",
language = "English (US)",
volume = "79",
pages = "806--813",
journal = "Journal of Consulting and Clinical Psychology",
issn = "0022-006X",
publisher = "American Psychological Association Inc.",
number = "6",

}

Ginsburg, GS, Kendall, PC, Sakolsky, D, Compton, SN, Piacentini, J, Albano, AM, Walkup, JT, Sherrill, J, Coffey, KA, Rynn, MA, Keeton, CP, McCracken, JT, Bergman, L, Iyengar, S, Birmaher, B & March, J 2011, 'Remission after acute treatment in children and adolescents with anxiety disorders: Findings from the CAMS', Journal of Consulting and Clinical Psychology, vol. 79, no. 6, pp. 806-813. https://doi.org/10.1037/a0025933

Remission after acute treatment in children and adolescents with anxiety disorders : Findings from the CAMS. / Ginsburg, Golda S.; Kendall, Philip C.; Sakolsky, Dara; Compton, Scott N.; Piacentini, John; Albano, Anne Marie; Walkup, John T.; Sherrill, Joel; Coffey, Kimberly A.; Rynn, Moira A.; Keeton, Courtney P.; McCracken, James T.; Bergman, Lindsey; Iyengar, Satish; Birmaher, Boris; March, John.

In: Journal of Consulting and Clinical Psychology, Vol. 79, No. 6, 01.12.2011, p. 806-813.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Remission after acute treatment in children and adolescents with anxiety disorders

T2 - Findings from the CAMS

AU - Ginsburg, Golda S.

AU - Kendall, Philip C.

AU - Sakolsky, Dara

AU - Compton, Scott N.

AU - Piacentini, John

AU - Albano, Anne Marie

AU - Walkup, John T.

AU - Sherrill, Joel

AU - Coffey, Kimberly A.

AU - Rynn, Moira A.

AU - Keeton, Courtney P.

AU - McCracken, James T.

AU - Bergman, Lindsey

AU - Iyengar, Satish

AU - Birmaher, Boris

AU - March, John

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Objective: To report on remission rates in anxious youth who participated in the Child/Adolescent Anxiety Multimodal Study (CAMS). The CAMS, a multisite clinical trial, randomized 488 children and adolescents (ages 7-17 years; 79 Caucasian; 50 female) with separation, social, and/or generalized anxiety disorder to a 12-week treatment of sertraline (SRT), cognitive behavioral therapy (CBT), their combination (COMB), or clinical management with pill placebo (PBO). Method: The primary definition of remission was loss of all study-entry anxiety disorder diagnoses; additional definitions of remission were used. All outcomes were rated by independent evaluators blind to treatment assignment. Predictors of remission were also examined. Results: Remission rates after 12 weeks of treatment ranged from 46 to 68 for COMB, 34 to 46 for SRT, 20 to 46 for CBT, and 15 to 27 for PBO. Rates of remission (i.e., achieving a nearly symptom-free state) were significantly lower than rates of response (i.e., achieving a clinically meaningful improvement relative to baseline) for the entire sample. Youth who received COMB had significantly higher rates of remission compared to all other treatment groups. Both monotherapies had higher remission rates compared to PBO, but rates were not different from each other. Predictors of remission were younger age, nonminority status, lower baseline anxiety severity, absence of other internalizing disorders (e.g., anxiety, depression), and absence of social phobia. Conclusions: For the majority of children, some symptoms of anxiety persisted, even among those showing improvement after 12 weeks of treatment, suggesting a need to augment or extend current treatments for some children.

AB - Objective: To report on remission rates in anxious youth who participated in the Child/Adolescent Anxiety Multimodal Study (CAMS). The CAMS, a multisite clinical trial, randomized 488 children and adolescents (ages 7-17 years; 79 Caucasian; 50 female) with separation, social, and/or generalized anxiety disorder to a 12-week treatment of sertraline (SRT), cognitive behavioral therapy (CBT), their combination (COMB), or clinical management with pill placebo (PBO). Method: The primary definition of remission was loss of all study-entry anxiety disorder diagnoses; additional definitions of remission were used. All outcomes were rated by independent evaluators blind to treatment assignment. Predictors of remission were also examined. Results: Remission rates after 12 weeks of treatment ranged from 46 to 68 for COMB, 34 to 46 for SRT, 20 to 46 for CBT, and 15 to 27 for PBO. Rates of remission (i.e., achieving a nearly symptom-free state) were significantly lower than rates of response (i.e., achieving a clinically meaningful improvement relative to baseline) for the entire sample. Youth who received COMB had significantly higher rates of remission compared to all other treatment groups. Both monotherapies had higher remission rates compared to PBO, but rates were not different from each other. Predictors of remission were younger age, nonminority status, lower baseline anxiety severity, absence of other internalizing disorders (e.g., anxiety, depression), and absence of social phobia. Conclusions: For the majority of children, some symptoms of anxiety persisted, even among those showing improvement after 12 weeks of treatment, suggesting a need to augment or extend current treatments for some children.

KW - adolescents

KW - anxiety

KW - children

KW - remission

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=82955193857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955193857&partnerID=8YFLogxK

U2 - 10.1037/a0025933

DO - 10.1037/a0025933

M3 - Article

VL - 79

SP - 806

EP - 813

JO - Journal of Consulting and Clinical Psychology

JF - Journal of Consulting and Clinical Psychology

SN - 0022-006X

IS - 6

ER -